High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials

Cancer

Volumn 107, Issue 1, 2006, Pages 116-124

  Kern, Wolfgang ^a   Estey, Elihu H ^b  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myeloid leukemia; High dose cytosine arabinoside; Review; Standard dose cytosine arabinoside

Indexed keywords

CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG MEGADOSE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

ADOLESCENT; ADULT; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS;

EID: 33745294373     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21543     Document Type: Review

References (12)

1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341:1051-1062.
2. National Cancer Institute. SEER cancer statistics review, 1973-1996. NIH Pub. No. 99-2789. Bethesda: National Cancer Institute; 1999.
3. Rowley JD. Molecular genetics in acute leukemia. Leukemia. 2000;14:513-517.
4. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322-2333.
5. Schoch C, Haferlach T, Haase D, et al. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol. 2001;112: 118-126.
6. Burnett AK. Tailoring the treatment of acute myeloid leukemia. Curr Opin Hematol. 1999;6:247-252.
7. Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int. J Epidemiol. 2002;37:150-153.
8. Der Simonian R. Maximum likelihood estimation of a mixing distribution. Appl Stat. 1986;35:302-309.
9. L'Abbe KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med. 1987;107:224-233.
10. Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996;87:1710-1717.
11. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996;88:2841-2851.
12. Buchner T, Hiddemann W, Wormann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood. 1999;93:4116-4124.